This decision is a blow for Eli Lilly and Novo Nordisk, who had both previously endorsed the proposed expansion.

India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White ...

Due to current legislation, Medicare Part D or C plans may only cover Zepbound for obstructive sleep apnea. However, the Centers for Medicare & Medicaid Services may expand weight loss medication ...

Prior to Friday's decision, the Obesity Action Coalition along with 80 other organizations sent a letter to HHS Secretary ...

Emergency room visits attributed to popular weight loss drugs such as Ozempic and Wegovy remain quite rare overall, but do ...

An analysis of differential coding patterns between Medicare Advantage (MA) and Traditional Medicare (TM) plans estimated how much coding differs between insurers and how much extra revenue insurers ...

CMS proposal to include obesity drugs like Novo Nordisk A/S’ Wegovy (semaglutide) and Eli Lilly and Co.’s Zepbound (tirzepatide) under Medicaid and Medicare didn’t make it far under the new U.S.

More than 7 million people would have gained coverage to the medicine, CMS said when it proposed the rule.

President Donald Trump's administration has decided not to cover expensive, high-demand obesity treatments under the federal ...

"I've said this before, but as more data comes in I become more convinced that we may look back on these drugs as the ...